Testosterone-induced Muscle Memory and Underlying Mechanisms

Skeletal Muscle Physiology Clinical Trial

Official title:

Long-term Effects of Anabolic Androgenic Steroids on Muscle Growth Potential: Testosterone-induced Muscle Memory and Underlying Mechanisms

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06188767
• Other study ID #: TESTO
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 1, 2024
• Est. completion date: September 1, 2025

Study information

• Verified date: December 2023
• Source: University of Copenhagen
• Contact: Lukas Moesgaard
• Phone: +4561724440
• Email: lm[@]nexs.ku.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this project is to investigate underlying mechanisms of testosterone- and resistance training-induced muscle hypertrophy and muscle memory in humans.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: September 1, 2025
• Est. primary completion date: September 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Healthy men and women
• BMI of <26 and normal ECG and blood pressure

Exclusion Criteria:

• Smoking
• Chronic disease,
• Use of prescription medication
• Pain due to current or previous musculoskeletal injury
• Resistance training more than once per week in the 12 months leading up to the intervention
• Current or previous use of prohibited anabolic substances

Related Conditions & MeSH terms

• Skeletal Muscle Physiology

Intervention

Drug:
• Testosterone Undecanoate
Following testosterone/placebo injection, participants undergo supervised resistance training for 4 weeks. This period is followed by a washout of 16 weeks with no drug and resistance training. Thereafter, another 4-week period with supervised resistance training is commenced, with no drug.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Morten Hostrup, PhD

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fiber cross-sectional area	Immunohistochemistry to determine fiber cross-sectional area	The change in fiber cross-sectional is assessed at baseline, 4, 20 and 24 weeks
Primary	Myonuclei	Immunohistochemistry to determine number of myonuclei	The change in myonuclei is assessed at baseline, 4, 20 and 24 weeks
Primary	Skeletal muscle proteome	Pathway enrichment analysis of the muscle proteome using mass spectrometry-based proteomics	The change in the muscle proteome is assessed at baseline, 4, 20 and 24 weeks
Secondary	Lean mass	Lean mass assessed by dual X-ray absorptiometry (DXA)	The change in lean mass is assessed at baseline, 4, 20 and 24 weeks
Secondary	Satellite cells	Immunohistochemistry to determine number of satellite cells	The change in satellite cells is assessed at baseline, 4, 20 and 24 weeks
Secondary	Muscle strength	1-repetition maximum	The change in 1-repetition maximum is assessed at baseline, 4, 20 and 24 weeks